44 results on '"Picca, Alberto"'
Search Results
2. A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation
3. Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma long-term survivors reveal a distinct group of tumors with MAPK pathway alterations
4. REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas
5. Integrative multi-omics networks identify PKCδ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy
6. Epstein-Barr Virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments
7. Basic premises: searching for new targets and strategies in diffuse gliomas
8. Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience
9. Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results
10. Neurological complications of immunotherapy and monoclonal antibody therapy
11. Contributors
12. A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation
13. Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic Perspectives
14. CTNI-33. TARGET TRIAL: A PHASE I/II OPEN-LABEL MULTICENTER STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFICACY OF AZD4547 IN PATIENTS WITH RELAPSED/REFRACTORY FGFR FUSION POSITIVE GLIOMA
15. EXTH-83. BIRC3 AS A PREDICTOR OF OUTCOME AND A NEW THERAPEUTIC TARGET IN TMZ RESISTANT GLIOBLASTOMA TUMORS
16. Anti–Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors
17. Advances in molecular and imaging biomarkers in lower-grade gliomas.
18. Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity
19. Late-onset vascular complications of radiotherapy for primary brain tumors: a case–control and cross-sectional analysis
20. Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice
21. EPCO-03. PATHWAY-BASED STRATIFICATION OF GLIOBLASTOMA BY MULTI-OMICS INFORMS SUBTYPE-SPECIFIC MASTER KINASES-PHOSPHOSITE SUBSTRATES
22. BIOM-35. A NEW PRECISION-MEDICINE APPROACH TO PREDICT TUMOR TREATMENT RESPONSE IDENTIFIES IN GLIOBLASTOMA A 17 GENE SIGNATURE PROGNOSTIC OF TMZ RESPONSE AND SURVIVAL WITH ROBUST PREDICTIVE VALUE
23. Current and future tools for determination and monitoring of isocitrate dehydrogenase status in gliomas
24. Peripheral neuropathies after BRAF and/or MEK inhibitor treatment: A pharmacovigilance study
25. FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas
26. Innovating Strategies and Tailored Approaches in Neuro-Oncology
27. Referee report. For: Associations among smoking, IDH mutations, MGMT promoter methylation, and grading in glioma: a cross-sectional study [version 1; peer review: 1 approved with reservations, 1 not approved]
28. Progressive multifocal leukoencephalopathy after first-line radiotherapy and temozolomide for glioblastoma
29. Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience
30. Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors
31. Adult brainstem glioma: a multicentre retrospective analysis of 47 Italian patients.
32. FGFR1 actionable mutations, molecular specificities and outcome of adult midline gliomas - additional materials
33. The clinical use of IDH1 and IDH2 mutations in gliomas
34. Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions.
35. Actionable targets involving FGF receptors in gliomas: Molecular specificities, spatial distribution, clinical outcome and radiological phenotype.
36. FGFR1actionable mutations, molecular specificities, and outcome of adult midline gliomas
37. Current therapeutic approaches to diffuse grade II and III gliomas
38. Diffuse gliomas with FGFR3‐TACC3 fusion have characteristic histopathological and molecular features
39. Targeting glioblastoma stem-cells: a recurrent challenge in neuro-oncology
40. Diffuse gliomas with FGFR3‐TACC3 fusion have characteristic histopathological and molecular features.
41. actionable mutations, molecular specificities, and outcome of adult midline gliomas.
42. Integrative multi-omics networks identify PKCδ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy
43. TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma.
44. Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.